Other Search Results
Incretin

Most of the earliest incretin-targeting agents to be approved fell into the class of DPP-4 inhibitors; these inhibit DPP-4 and thus prevent the enzymatic degradation of GLP-1 and GIP. The...

NAVER 학술정보 > Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibi....

저자 : Goldenberg Ronald M, Verma Subodh, Perkins Bruce A, Gilbert Jeremy D, Zinman Bernard, 소속 : LMC Diabetes & Endocrinology, Thornhill, Ontario, Canada Division of Cardiac Surgery, Department of Surgery, Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada Division of Endocrinology and Metabolism, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada Division of Endocrinology and Metabolism, Sunnybrook Health Sciences Centre, Toronto, Ontario, ...

Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile th....

Affiliations 1 LMC Diabetes & Endocrinology, Thornhill, Ontario, Canada. Electronic address: ****************@*****.***. 2 Division of Cardiac Surgery, Department of Surgery, Li Ka Shing...

[논문]Incretin agents in type 2 diabetes. - 과학기술 지식인프라 ScienceON (사이언스온)

OBJECTIVE: To evaluate the emerging classes of antihyperglycemic agents that target the incretin pathway, including their therapeutic efficacy and side effect profiles, in order to help identify th...

Use of incretin agents and risk of acute and chronic pancreatitis: A population-

Abstract Aim: To determine the association between the use of incretin agents (dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists) for the treatment of type 2...

The Role of Oral Antidiabetic Agents and Incretin Mimetics in Type 2 Diabetic Patients with Non-Alcoholic....

Volume 20, Issue 22, 2014 · Page: [3705 - 3715] Pages: 11 · DOI: 10.2174/13816128113196660676 · Price: $65

[논문]Differentiating among incretin therapies: a multiple‐target approach to type - 과학기술 지식인프라....

SummaryWhat is known and Objective: Incretin‐based glucagon‐like peptide‐1 receptor... peptide‐1 receptor agonists #incretin therapy #liraglutide #type 2 diabetes

Incretin-based therapy in type 2 diabetes: An evidence based systematic review a

Long acting GLP-1Ra were more effective in HbA1c lowering than short-acting agents but with similar weight loss effect. The effect of DPP-4i incretin glycemic efficacy was not modified by...

Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Coh....

OBJECTIVE · Concerns have been raised about a possible increased risk of pancreatic cancer associated with incretin-based therapies. We examined the risk of pancreatic cancer among patients with diabetes prescribed incretin drugs. RESEARCH DESIGN AND METHODS · With the use of public health insurance databases of Belgium and the Lombardy Region, Italy, we created two retrospective cohorts that included adult patients who were first prescribed an incretin drug or another noninsulin antidiabetic drug (NIAD) from 1 July 2008 to 31 December 2013 i ...

Differentiating among incretin therapies: a multiple-target approach to type 2 d

edu Abstract What is known and objective: Incretin-based... Incretin therapies are compared with their mechanisms of action... Randomized, head-to-head comparison studies among incretin...

Copyright © www.babybloodtype.com. All rights reserved.
policy sang_list